Committed to trials of LDN as a treatment for autoimmune diseases

Text Resize

-A +A
Low Dose Naltrexone (LDN) is a drug that may help regulate a dysfunctional immune system in autoimmune diseases.

About LDN Research Trust

The LDN Research Trust was set up by a small core of people who have Multiple Sclerosis. The primary aim of the Trust is to initiate Clinical Trials of Low Dose Naltrexone.

Whilst working to raise funds for trials, we have helped over 14,000 people  to obtain LDN from a General Practitioner or Neurologist, either through the National Health Service or by private prescription.  We have also been able to help people, not just in the UK but in countries throughout Europe, as well as USA, Canada, West Indies, Australia, New Zealand, and others. 

Find out more

LDN Aware

The mission of LDN aware is to spread public awareness of LDN worldwide.

Low dose naltrexone, where naltrexone is used in doses approximately one-tenth those used for drug/alcohol rehabilitation purposes, is being used as an "off-label" treatment for certain immunologically-related disorders. The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.  

Find out more

Sign up to our Newsletter

The LDN 2013 AIIC Conference - 5th October 2013

The LDN 2013 AIIC Conference was a charity event organised by the LDN Research Trust and Mark Drugs, which was held at Harper College, Palatine Illinois on 5th October 2013.

The recording of the conference is now availabe online at the cost of $40 for unlimted viewing,

The conference reviewed, compared and contrasted the most recent data and treatments for a variety of Auto-Immune and Immuno-modulated Conditions.

 

Featured Video